Neurobehavioral development of neonatal mice following blockade of VIP during the early embryonic period.
Previous work has shown that blockade of VIP function in the early postimplantation embryo results in growth retardation and microcephaly. In the present work, the neurobehavioral development of neonatal mice was examined following treatment of dams with a VIP antagonist during this period. Inhibition of VIP functions during early embryogenesis impaired the performance of 5 of 10 developmental behaviors. These behaviors included developmental milestones (first appearance of ear twitch and eye opening) and complex motor behaviors (negative geotaxis, surface righting, and air righting). The retardation of neurobehavioral development produced by inhibition of VIP action indicates that this peptide is important to the progression of embryonic development.
Wu
J Y
JY
Section on Developmental and Molecular Pharmacology, NICHD, NIH, Bethesda, MD 20892, USA.
Henins
K A
KA
Gressens
P
P
Gozes
I
I
Fridkin
M
M
Brenneman
D E
DE
Hill
J M
JM
D000818:Animals; D000831:Animals, Newborn; D001522:Behavior, Animal / Q000187:drug effects / Q000502:physiology*; D001835:Body Weight / Q000187:drug effects / Q000502:physiology; D047108:Embryonic Development; D005314:Embryonic and Fetal Development / Q000187:drug effects* / Q000502:physiology; D005260:Female; D006131:Growth Inhibitors / Q000494:pharmacology; D051379:Mice; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology; D009496:Neurotensin / Q000494:pharmacology; D011247:Pregnancy; D011993:Recombinant Fusion Proteins / Q000494:pharmacology; D014660:Vasoactive Intestinal Peptide / Q000037:antagonists & inhibitors* / Q000494:pharmacology / Q000502:physiology
D006131:Growth Inhibitors; D011993:Recombinant Fusion Proteins; C069189:(VIP-neurotensin) hybrid antagonist; D014660:Vasoactive Intestinal Peptide; D009496:Neurotensin